GO and KEGG analysis. by Wan-Jing Zhen (20427813)

Subjects:

S3 Fig - by Wan-Jing Zhen (20427813)

Subjects:

KEGG enrichment analysis. by Wan-Jing Zhen (20427813)

Subjects:

GSEA results. by Wan-Jing Zhen (20427813)

Subjects:

GO enrichment analysis. by Wan-Jing Zhen (20427813)

Subjects:

37%, 63%, and 100% amplitude (mm) and latency (ms). by Tomoe Hayakawa (20978784)

Subjects:

Impact of group 1 and group 2 drugs on hyperglycemia based on HbA1c levels before and after 3 months of administration. by Nadia Gul (249538)

Subjects:

The complex interplay between SGLT-2is, RAAS, and glucose metabolism in type 2 diabetes mellitus patients. by Ningning Wang (560944)

Subjects:

Time Course of the RAAS. by Ningning Wang (560944)

Subjects:

Experimental design. by Amy J. Schuh (8520354)

Subjects:

Effects of SGLT-2is during the time course. by Ningning Wang (560944)

Subjects:

Changes of physical and biochemical indicators from baseline and difference between DKD and non-DKD patients. by Ningning Wang (560944)

Subjects:

Baseline characteristics between DKD and non-DKD patients. by Ningning Wang (560944)

Subjects:

Flow diagram of patient recruitment. by Ningning Wang (560944)

Subjects:

Data used to generate Figs 2–7 and S1 Fig. by Amy J. Schuh (8520354)

Subjects:

Spearman correlation analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients. by Ningning Wang (560944)

Subjects:

Multiple linear regression analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients. by Ningning Wang (560944)

Subjects:

PRISMA flowchart of the included studies. by Gaelle Salame (21077899)

“…On the other hand, patients in the immunotherapy group had significantly decreased HbA1c levels (MD = -0.63; 95% CI: [-1.18, -0.07]; p = 0.03), indicating that immunotherapy had a positive impact on glycemic management. …”

Characteristics of Included Studies. by Gaelle Salame (21077899)

“…On the other hand, patients in the immunotherapy group had significantly decreased HbA1c levels (MD = -0.63; 95% CI: [-1.18, -0.07]; p = 0.03), indicating that immunotherapy had a positive impact on glycemic management. …”

Fig 6 - by Samuel Hylander (331771)